Patchouli Oil

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: skin stress mood

Research Overview

Across the abstracts, research on Pogostemon cablin (patchouli) and its essential oil is most developed in (i) phytochemical characterization and (ii) preclinical pharmacology of isolated sesquiterpenes. Reviews describe a chemically complex oil (>140 identified constituents), with repeated emphasis on major components such as patchouli alcohol and β‑patchoulene, alongside other terpenoids and phenolic compounds. Experimental studies then focus on mechanistic, disease-model testing of specific purified constituents (e.g., patchouli alcohol, β‑patchoulene, patchoulene epoxide), typically in rodent models and cell lines, and on arthropod-control applications (mosquito toxicity screens; tick repellency assays). Overall, the literature represented here is dominated by laboratory and animal studies rather than human clinical research.

The strongest evidence in these abstracts supports anti-inflammatory and antioxidant actions in vivo, with convergent mechanistic signals across models. Patchoulene epoxide reduced ethanol-induced gastric injury in rodents, associated with modulation of NF‑κB–related signaling, restoration of pro-/anti-inflammatory cytokine balance, increased endogenous antioxidant enzymes (GSH, SOD, CAT), reduced lipid peroxidation (MDA), and reduced apoptosis markers (e.g., caspase-3/Fas pathway), consistent with a multi-pathway gastroprotective profile. β‑Patchoulene showed protective effects in inflammatory injury models (e.g., LPS-induced acute lung injury) with reductions in inflammatory cytokines and oxidative stress markers, and it also improved diet- and FFA-induced hepatic steatosis with evidence consistent with AMPK pathway activation (including inhibitor-based support using Compound C). Patchouli alcohol demonstrated antidepressant-like effects in a chronic stress rodent model, linked to hippocampal mTOR signaling and autophagy/synaptic markers, with pharmacologic manipulation (rapamycin, chloroquine) supporting pathway involvement. In vector-control studies, patchouli oil showed measurable insecticidal activity against mosquitoes, but potency was far lower than synthetic pyrethroids; tick repellent work underscores assay- and delivery-dependent performance and highlights the broader challenge of translating lab repellency to field efficacy.

Key gaps are translational and standardization-related. Many traditional uses (e.g., for gastrointestinal symptoms, infections, mood, and pain) remain insufficiently verified in humans, and the current evidence base is largely preclinical with limited information on clinical efficacy, dosing, safety, pharmacokinetics, and drug–herb interactions. Because essential oil composition varies by source, storage, and processing, more work is needed on chemical standardization, authentication, and linking specific constituents (and mixtures) to reproducible bioactivity. Additional priorities include comparative effectiveness versus existing therapies, rigorous toxicology (including dermal/inhalational exposure relevant to aromatherapy and repellents), and well-designed clinical trials in the most promising indications suggested by mechanistic animal data (inflammation-related conditions, metabolic liver disease, and mood disorders), alongside formulation and delivery studies for vector-control applications.

1. What conditions has Patchouli Oil been studied for?

  • Depression / stress-related depressive symptoms (preclinical): Patchouli alcohol (a major constituent of patchouli oil) was studied in a chronic unpredictable mild stress (CUMS) rat model of depression.

  • Non-alcoholic fatty liver disease (NAFLD) / hepatic steatosis (preclinical): β-patchoulene (a representative component of patchouli oil) was studied in high-fat diet (HFD) rats and in fatty-acid–loaded L02 liver cells.

  • Acute lung injury (ALI) / severe inflammation (preclinical): β-patchoulene was studied in an LPS-induced acute lung injury mouse model.

  • Gastric ulcer / gastritis-like injury (preclinical): Patchoulene epoxide (from long-stored patchouli oil) was studied in an ethanol-induced gastric ulcer model.

  • UV-induced skin photoaging (preclinical, topical): Patchouli oil (standardized to ~28.2% patchouli alcohol) was studied in a mouse UV photoaging model.

  • Insecticidal/repellent applications (vector/pest control, not human treatment): Patchouli oil was tested for mosquito toxicity (Aedes aegypti, Anopheles gambiae). A separate study tested repellency against Lone Star ticks but highlighted another compound (not patchouli oil specifically). Pogostone (a patchouli constituent) was tested as an insecticide/antifeedant against agricultural pests (Spodoptera spp.).

  • Antibacterial materials (non-medical/adjunct use): Patchouli oil microcapsules grafted onto cotton fabric were tested for antibacterial activity against Staphylococcus aureus and Escherichia coli.

  • Broad traditional uses and broad pharmacology (review-level): A review abstract lists traditional uses (e.g., colds, headache, fever, nausea/vomiting/diarrhea, abdominal pain, bites) and modern reported activities (e.g., antioxidant, analgesic, anti-inflammatory, antiplatelet/antithrombotic, antiemetic, antidepressant, cytotoxic), but also notes that some traditional uses still require verification and standardization.

2. Does it work in treating those conditions? Summarize the evidence.

  • Depression-like behavior (rats; patchouli alcohol): In CUMS rats, patchouli alcohol improved multiple depression-like behavioral measures (increased sucrose preference and exploratory activity; reduced immobility time). Mechanistically, it was associated with restoration of hippocampal mTOR pathway signaling (mTOR, p70S6K, 4E-BP-1 phosphorylation) and changes consistent with reduced autophagy and improved synaptic markers (PSD-95, SYN-I). The effect was blocked by rapamycin (mTOR inhibitor) and chloroquine (autophagic flux inhibitor), supporting pathway involvement. Limitations: animal model; not evidence of clinical antidepressant efficacy in humans.

  • NAFLD / hepatic steatosis (rats and liver cells; β-patchoulene): β-patchoulene reduced HFD-associated weight gain, hepatic injury, and lipid deposition in serum and liver, and reduced lipid accumulation in FFA-treated L02 cells. Benefits were linked to increased AMPK signaling and downstream lipid metabolism factors; the AMPK inhibitor Compound C abrogated benefits in vitro. Limitations: preclinical only; dosing, formulation, and human relevance are unknown.

  • Acute lung injury (mice; β-patchoulene): Pretreatment reduced mortality, lung edema (W/D ratio), and pathological injury in LPS-induced ALI. It lowered inflammatory cytokines (TNF-α, IL-6, IL-1β), reduced oxidative stress markers (MDA) and MPO activity, increased miR-146a, suppressed NF-κB activation, and upregulated Nrf2/HO-1 and antioxidant genes. Limitations: prevention/pretreatment model in mice; not evidence for treating established human ALI/ARDS.

  • Ethanol-induced gastric ulcers (animal model; patchoulene epoxide): Patchoulene epoxide reduced ulcer area and improved histology, with proposed mechanisms including NF-κB pathway modulation (p-IκBα/IκBα, p-p65/p65), increased antioxidant defenses (GSH, SOD, CAT), reduced lipid peroxidation (MDA), and reduced apoptosis markers (caspase-3, Fas/Fasl). Limitations: animal model; not clinical evidence for peptic ulcer disease in humans.

  • UV photoaging (mice; topical patchouli oil): Topical patchouli oil (6–9 mg/mouse) applied before UV exposure reduced wrinkle formation, improved elasticity, increased collagen content (~21.9% and ~26.3%), reduced epidermal thickening (~32.6%), and improved oxidative stress markers (lower MDA; higher SOD, GSH-Px, CAT). Limitations: mouse model; dosing and safety for routine human cosmetic/dermatologic use not established in these abstracts.

  • Mosquito control (topical application to insects; patchouli oil): Patchouli oil showed the highest toxicity among tested essential oils against Ae. aegypti and An. gambiae, but was still far less toxic than synthetic pyrethroids (about 1,700× less toxic than bifenthrin for Ae. aegypti; ~685× less toxic for An. gambiae). This supports activity but indicates it is much weaker than standard insecticides. Limitations: not a human health treatment; efficacy in real-world vector control depends on formulation and delivery.

  • Agricultural pests (pogostone): Pogostone showed antifeedant and larvicidal activity against Spodoptera litura and S. exigua (LC50 values reported for oral and contact toxicity). Limitations: pest-control context; not human therapeutic evidence.

  • Antibacterial textiles (patchouli oil microcapsules on fabric): Treated cotton showed ~65% antibacterial rate against S. aureus and E. coli even after 25 washes, suggesting a functional antimicrobial surface. Limitations: material science outcome; does not demonstrate treatment of human infections.

3. What health benefits does it have?

  • Anti-inflammatory and antioxidant effects (preclinical): Multiple abstracts implicate reduced inflammatory signaling (e.g., NF-κB suppression; lower TNF-α/IL-6/IL-1β) and improved antioxidant status (higher SOD, CAT, GSH/GSH-Px; lower MDA) in models of gastric injury, lung injury, and UV skin damage.

  • Potential mood-related benefits (preclinical): Patchouli alcohol produced antidepressant-like effects in stressed rats, associated with hippocampal mTOR signaling and synaptic/autophagy markers.

  • Metabolic/liver support signals (preclinical): β-patchoulene improved hepatic steatosis outcomes in HFD rats and liver cells, linked to AMPK pathway activation and lipid metabolism regulation.

  • Skin photoprotection / anti-photoaging (preclinical, topical): Patchouli oil improved wrinkles, elasticity, collagen, epidermal thickness, and oxidative stress markers in UV-exposed mice.

  • Potential supportive roles outside supplementation (non-therapeutic): Demonstrated insecticidal activity against mosquitoes (though much weaker than pyrethroids) and antibacterial performance when embedded in textiles.

  • Important caveat: Across these abstracts, benefits are largely based on animal or in vitro studies and on isolated constituents (patchouli alcohol, β-patchoulene, patchoulene epoxide, pogostone). Evidence that commercially used “patchouli oil” as a supplement treats human disease is not established here.

4. Does it have any downsides or side effects?

  • Human safety not established in these abstracts: The provided abstracts do not report human adverse events, tolerability, or drug interaction studies for patchouli oil or its constituents.

  • Preclinical focus and dosing uncertainty: Many findings involve pretreatment designs (e.g., UV photoaging, LPS lung injury) and specific doses in animals (e.g., 6–9 mg/mouse topical oil). Translation to safe and effective human dosing is unknown.

  • Potential for variability/quality issues: The review abstract emphasizes the need for standardizing and authenticating bioactivity of purified compounds. Essential oils can vary widely in composition; one study explicitly quantified patchouli alcohol (~28.2%) to ensure quality.

  • Potential irritation/sensitization (not addressed here): Many essential oils can cause skin irritation or allergic contact dermatitis in some users, especially when undiluted; however, this risk is not evaluated in the provided abstracts, so it cannot be confirmed or quantified from this evidence set.

  • Not a substitute for proven insect control: Patchouli oil was substantially less toxic to mosquitoes than synthetic pyrethroids in topical insect assays, implying that relying on it alone for vector control could be less effective.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are reported in the provided abstracts. There is no evidence here linking patchouli oil (or constituents such as patchouli alcohol, β-patchoulene, patchoulene epoxide, pogostone) to specific human genetic variants that alter efficacy or risk.

  • Mechanistic signals that are not pharmacogenomics: The abstracts describe pathway changes (e.g., mTOR signaling in depression-like behavior; AMPK signaling in NAFLD; NF-κB/Nrf2 and miR-146a in inflammation). These are biological mechanisms, but they are not tied to genotype-dependent responses in the evidence provided.

References

  1. A Comprehensive Review on the Phytochemical Constituents and Pharmacological Activities of Pogostemon cablin Benth.: An Aromatic Medicinal Plant of Industrial Importance.
    Mallappa Kumara Swamy, Uma Rani Sinniah (2015) - Molecules (Basel, Switzerland)
  2. A Comprehensive Review on Pharmacological Activities of Pachypodol: A Bioactive Compound of an Aromatic Medicinal Plant Pogostemon Cablin Benth.
    Sehrish Fatima, Iqra Farzeen, Asma Ashraf, Bilal Aslam, Muhammad Umar Ijaz, Sumreen Hayat, Muhammad Hassan Sarfraz, Saima Zafar, Nimrah Zafar, Jeremiah Oshiomame Unuofin, Sogolo Lucky Lebelo, Saima Muzammil (2023) - Molecules (Basel, Switzerland)
  3. Prophylactic efficacy of patchoulene epoxide against ethanol-induced gastric ulcer in rats: Influence on oxidative stress, inflammation and apoptosis.
    Jiali Liang, Yaoxing Dou, Xue Wu, Huilin Li, Jiazhen Wu, Qionghui Huang, Dandan Luo, Tiegang Yi, Yuhong Liu, Ziren Su, Jianping Chen (2018) - Chemico-biological interactions
  4. Repellent activity of essential oils to the Lone Star tick, Amblyomma americanum.
    Anais Le Mauff, Edmund J Norris, Andrew Y Li, Daniel R Swale (2024) - Parasites & vectors
  5. Patchouli alcohol protects against chronic unpredictable mild stress-induced depressant-like behavior through inhibiting excessive autophagy via activation of mTOR signaling pathway.
    Jianyi Zhuo, Baoyi Chen, Chaoyue Sun, Tao Jiang, Zhiwei Chen, Yanlu Liu, Juan Nie, Hongmei Yang, Jingna Zheng, Xiaoping Lai, Ziren Su, Chuwen Li, Yucui Li (2020) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Comparison of the Insecticidal Characteristics of Commercially Available Plant Essential Oils Against Aedes aegypti and Anopheles gambiae (Diptera: Culicidae).
    Edmund J Norris, Aaron D Gross, Brendan M Dunphy, Steven Bessette, Lyric Bartholomay, Joel R Coats (2015) - Journal of medical entomology
  7. β-patchoulene improves lipid metabolism to alleviate non-alcoholic fatty liver disease via activating AMPK signaling pathway.
    Nan Xu, Huijuan Luo, Minyao Li, Jiazhen Wu, Xue Wu, Liping Chen, Yuxuan Gan, Fengkun Guan, Mengyao Li, Ziren Su, Jiannan Chen, Yuhong Liu (2021) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. β-Patchoulene from patchouli oil protects against LPS-induced acute lung injury via suppressing NF-κB and activating Nrf2 pathways.
    Xiao-Ying Chen, Yao-Xing Dou, Dan-Dan Luo, Zhen-Biao Zhang, Cai-Lan Li, Hui-Fang Zeng, Zi-Ren Su, Jian-Hui Xie, Xiao-Ping Lai, Yu-Cui Li (2017) - International immunopharmacology
  9. Prevention of UV radiation-induced cutaneous photoaging in mice by topical administration of patchouli oil.
    Rong-Feng Lin, Xue-Xuan Feng, Chu-Wen Li, Xiao-Jun Zhang, Xiu-Ting Yu, Jiu-Yao Zhou, Xie Zhang, You-Liang Xie, Zi-Ren Su, Janis Ya-Xian Zhan (2014) - Journal of ethnopharmacology
  10. Study on the grafting of chitosan-gelatin microcapsules onto cotton fabrics and its antibacterial effect.
    Jiayi Liu, Chaohong Liu, Yingju Liu, Minjie Chen, Yang Hu, Zhuohong Yang (2013) - Colloids and surfaces. B, Biointerfaces
  11. Insecticidal activity of pogostone against Spodoptera litura and Spodoptera exigua (Lepidoptera: Noctuidae).
    Si-Han Huang, Ji-Dong Xian, Song-Zhi Kong, Yu-Cui Li, Jian-Hui Xie, Ji Lin, Jian-Nan Chen, Hong-Feng Wang, Zi-Ren Su (2014) - Pest management science
  12. Comparative Evaluation between Lavender Essential Oil and Patchouli Essential Oil in Aromatherapy and Its Effect on Dental Anxiety in Children.
    Santwana Tripathy, Anil Kohli, Karuna Sharma, Rahul Katyayan, Parkhi Bhatnagar, Najmus Sahar (2023) - International journal of clinical pediatric dentistry
  13. Experimental study on anti-inflammatory activity of a TCM recipe consisting of the supercritical fluid CO2 extract of Chrysanthemum indicum, Patchouli Oil and Zedoary Turmeric Oil in vivo.
    Ji-Yan Su, Li-Rong Tan, Ping Lai, Hai-Chun Liang, Zhen Qin, Mu-Rong Ye, Xiao-Ping Lai, Zi-Ren Su (2012) - Journal of ethnopharmacology
  14. Antidepressant-like Activity of Patchouli Oil var. Tapak Tuan (
    Puji Astuti, Khairan Khairan, Marthoenis Marthoenis, Kartini Hasballah (2022) - Pharmaceuticals (Basel, Switzerland)
  15. Patchouli oil ameliorates acute colitis: A targeted metabolite analysis of 2,4,6-trinitrobenzenesulfonic acid-induced rats.
    Xiuting Yu, Guanghua Yang, Hua Jiang, Shuhai Lin, Yuhong Liu, Xie Zhang, Huifang Zeng, Ziren Su, Song Huang, Linlin Shen, Xiaojun Zhang (2017) - Experimental and therapeutic medicine
  16. Patchouli oil isolated from the leaves of
    Qiong-Hui Huang, Xue Wu, Xiao-Hong Chen, Jia-Zhen Wu, Zi-Ren Su, Jia-Li Liang, Yu-Cui Li, Xiao-Ping Lai, Jian-Nan Chen, Yu-Hong Liu (2018) - RSC advances
  17. Patchouli Oil Attenuates High Fat Diet-induced Non-alcoholic Hepatic Steatosis.
    Nan Xu, Xue Wu, Hui-Juan Luo, Fang-Fang Xu, Qiong-Hui Huang, Jia-Zhen Wu, Yu-Xuan Gan, Min-Yao Li, Zheng-Quan Lai, Hui-Ran Lin, Jian-Nan Chen, Zi-Ren Su, Wei-Peng Ai, Yu-Hong Liu (2020) - Planta medica
  18. Preparation of Patchouli Oil Microemulsion Gel and Its Topical Application to Ameliorate Atopic Dermatitis in Mice.
    Tingting Chen, Changjin Xu, Min Wang, Yan Cui, Riqing Cheng, Wenyao Zhang, Xin Gao, Laibing Wang, Herima Qi, Shuyan Yu, Jianping Chen, Lan Ma, Huiqing Guo (2024) - Gels (Basel, Switzerland)
  19. Unveiling the phyto-restorative potential of ethereal distillates for atopic dermatitis: an advanced therapeutic approach.
    Ritchu Babbar, Parth Sharma, Rashmi Arora, Twinkle Sharma, Madhukar Garg, Sumitra Singh, Satyender Kumar, Rakesh K Sindhu (2025) - Journal of complementary & integrative medicine
  20. A bigel co-delivering highly hydrophilic and hydrophobic natural compounds for enhanced ulcerative colitis therapy.
    Yueqian Wu, Yuting Jiang, Yihao He, Yanli Luo, Zhiwen Gu, Yanfeng Xiu, Bing Wang, Yongzhuo Huang (2025) - International journal of pharmaceutics


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!